Pharmaceutical Market Access and Drug Affordability in Low-Income Nations
DOI:
https://doi.org/10.5281/zenodo.14722680Keywords:
pharmaceutical, access to market, drug affordability, low income countriesAbstract
The pharmaceutical industry is going through a paradigm shift, and the dynamics of the sector are increasingly being shaped by emerging markets. The study aimed at examining the impact of regulation of distribution chains and tariff/tax exemptions on pharmaceutical market access and drug affordability in low income countries. The study adopts cross sectional research design. Furthermore, the research method for this study is survey. The study population covered the total population of top management staff of pharmaceutical companies in Nigeria. The study adopted a total of 50 respondents drawn from the total population of the study using the convenient sampling technique. A structured questionnaire was used as instrument of data collection and the collected data were analysed with mean and standard deviation. The study concluded that regulations play a crucial role in streamlining distribution processes, leading to improvements in supply chain logistics and Tariff and tax exemptions play a crucial role in enhancing the availability and accessibility of essential medicines, particularly for vulnerable populations in low-income countries. The study recommended that lowering costs, these exemptions not only improve the diversity and availability of pharmaceuticals but also address significant gaps in supply. Additionally, tax and tariff incentives attract investment from international pharmaceutical companies and organizations, strengthening drug supply chains and fostering strategic partnerships.
Downloads
References
Angelis, A., Lange, A., & Kanavos, P. (2018). Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. European Journal of Health Economics, 19(1), 123–152.
Bastone, A., Schiavone, F., Carli, M. R., & Juárez-Varón, D. (2023). How to shorten the market entry innovation in a highly regulated market. The case of early access programs in the pharmaceutical industry. International Entrepreneurship and Management Journal.
Belloni, A., Morgan, D., & Paris, V. (2016). Pharmaceutical expenditure and policies: Past trends and future challenges. OECD Health Working Papers, 87. https://doi.org/10.1787/5jm0q1f4cdq7-en 5.
Blichfeldt, H., & Faullant, R. (2021). Performance effects of digital technology adoption and product & service innovation – A process-industry perspective. Technovation.
Bradfield, R., & El-Sayed, H. (2019). Four scenarios for the future of the pharmaceutical industry. Technology Analysis and Strategic Management, 21(2), 195–212.
Chib, A., Van Velthoven, M. H., & Car, J. (2015). MHealth adoption in low-resource environments: A review of the use of mobile healthcare in developing countries. Journal of Health Communication, 20(1), 4–34.
Critchley, G. J., & Zaric, G. S. (2019). The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare. Health Economics (United Kingdom), 28(8), 1035–1051.
Danzon, P. M., Mulcahy, A. W., & Towse, A. K. (2015). Pharmaceutical pricing in emerging markets: Effects of income, competition, and procurement. Health Economics (United Kingdom), 24(2), 238–252.
Davila, A., Rodriguez-Lluesma, C., & Elvira, M. M. (2018). Engaging stakeholders in emerging economies: The case of multilatinas. Journal of Business Ethics, 152(4), 949–964.
Demir, M., & Min, M. (2019). Consistencies and discrepancies in corporate social responsibility reporting in the pharmaceutical industry. Sustainability Accounting, Management and Policy Journal, 10(2), 333–364.
Farouk, A., Alahmadi, A., Ghose, S., & Mashatan, A. (2020). Blockchain platform for industrial healthcare: Vision and future opportunities. Computer Communications, 154, 223–235
Gautam, A., & Pan, X. (2016). The changing model of big pharma: Impact of key trends. Drug Discovery Today, 21(3), 379–384).
Ijzerman, M. J., Koffijberg, H., Fenwick, E., & Krahn, M. (2017). Emerging use of early health technology assessment in medical product development: A scoping review of the literature. PharmacoEconomics 35(7), 727–740.
Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S. (2016). Prices, costs, and affordability of new medicines for hepatitis c in 30 countries: An economic analysis. PLoS Medicine, 13(5).
Jommi, C., Otto, M., Armeni, P., & De Luca, C. (2012). Market access management by pharmaceutical companies in a complex environment: The Italian case study. Journal of Medical Marketing, 12(2), 93–103.
Kamsu-Foguem, B., & Foguem, C. (2014). Telemedicine and mobile health with integrative medicine in developing countries. Health Policy and Technology, 3(4), 264–271.
Kim, Y. C., Atukeren, E., & Lee, Y. (2022). A new digital value chain model with PLC in biopharmaceutical industry: The implication for open innovation. Journal of Open Innovation: Technology, Market, and Complexity, 8(2).
Koch, M. A. (2015). Pharmaceutical market access: Current state of affairs and key challenges–results of the Market Access Launch Excellence Inventory (MALEI). Journal of Market Access and Health Policy, 3(1).
Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: A Review. AAPS Journal, 24(1), 56-66
Koromina, M., Pandi, M. T., & Patrinos, G. P. (2019). Rethinking drug repositioning and development with artificial intelligence, machine learning, and omics. OMICS A Journal of Integrative Biology, 23(11), 539–548.
Kostyak, L., Shaw, D. M., Elger, B., & Annaheim, B. (2017). A means of improving public health in lowand middle-income countries? Benefits and challenges of international public–private partnerships. Public Health, 149(1), 120–129.
Roemer-Mahler, A. (2014). The rise of companies from emerging markets in global health governance: Opportunities and challenges. Review of International Studies, 40(5), 897–918.
Rühli, E., Sachs, S., Schmitt, R., & Schneider, T. (2017). Innovation in multi stakeholder settings: The case of a wicked issue in health care. Journal of Business Ethics, 143(2), 289–305.
Selvaraj, C., Chandra, I., & Singh, S. K. (2022). Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Molecular Diversity, 26(3) 1893–1913.
Sendyona, S., Odeyemi, I., & Maman, K. (2016a). Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. Journal of Market Access and Health Policy, 4(1).
Sendyona, S., Odeyemi, I., & Maman, K. (2016b). Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. Journal of Market Access and Health Policy, 4(1).
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2025 Agbeni Kehinde Emmanuel
This work is licensed under a Creative Commons Attribution 4.0 International License.
Research Articles in 'Applied Science and Biotechnology Journal for Advanced Research' are Open Access articles published under the Creative Commons CC BY License Creative Commons Attribution 4.0 International License http://creativecommons.org/licenses/by/4.0/. This license allows you to share – copy and redistribute the material in any medium or format. Adapt – remix, transform, and build upon the material for any purpose, even commercially.
